# LyGenesis

Canonical page: https://technooptimist.io/companies/lygenesis
Pittsburgh biotech that grows new organ tissue inside a patient's own lymph nodes. Its lead therapy injects donor liver cells into lymph nodes to grow a second, small liver in people with end-stage liver disease.

## In brief

- Uses lymph nodes as living bioreactors: donor cells injected there grow into working ectopic liver, without major surgery.
- Phase 2a in end-stage liver disease at Houston Methodist; first cohort cleared for dose escalation in March 2025.
- Same idea in preclinical work for thymus (immune aging), pancreatic islets and kidney.

## Facts

- Headquarters: US
- Status: private
- Website: https://www.lygenesis.com
- Frontiers: [Longevity](https://technooptimist.io/longevity.md) (Replacement & regeneration), [Biotech](https://technooptimist.io/biotech.md)

## Programs

- [LYG-LIV-001 ectopic liver](https://technooptimist.io/longevity/lyg-liv-001.md) (Longevity): Pilot; next: Cohort 2: 150M cells across 3 lymph nodes. Phase 2a dose escalation: cohort 1 (4 patients) cleared; higher doses across more lymph nodes next.

## Technical approach

- **Lymph node as bioreactor: Grow tissue where it has blood and room**: Lymph nodes are well supplied with blood and can expand; liver cells placed there multiply and form functioning liver tissue away from the scarred native organ.
- **Donor organs stretched: One liver for dozens of patients**: Cells come from donated livers that missed a transplant match; one liver holds hundreds of billions of hepatocytes, enough for 50+ patients (company estimate).
- **Outpatient delivery: A 10-minute endoscopic injection**: Cells are injected through an endoscope with ultrasound guidance into nodes near the gut, under light sedation, instead of a transplant operation.

## Open problems

- **How much liver is enough** (active research): The company targets a 10–20% boost in liver function; whether ectopic tissue in humans grows that much is what the dose-escalation trial must show.
- **Immune rejection** (active research): Donor cells can be rejected; with iTolerance the company is testing a local tolerance gel to avoid lifelong immune-suppressing drugs.
- **Kidney plumbing** (open): Ectopic kidneys can form, but draining their urine out of a lymph node is unsolved, keeping that program early.

## Latest updates

- **1 Oct 2026**: LyGenesis CEO details dose plan: 50M liver cells in one lymph node, rising to 250M across five, with no serious adverse events so far. At LSX US 2026, CEO Michael Hufford said the first cohort received 50 million hepatocytes in a single lymph node with no serious adverse events, and that later cohorts get 150 million cells across three nodes and 250 million across up to… ([our story](https://technooptimist.io/stories/lygenesis-ceo-details-dose-plan-50m-liver-cells-in-one-lymph-node-2477375b.md) · [original source](https://www.bioxconomy.com/growth-strategy/lygenesis-grows-ectopic-livers-inside-lymph-nodes))
- **4 Mar 2025**: Safety board clears LyGenesis ectopic-liver trial to escalate dose after first four patients. The trial's Data and Safety Monitoring Board reviewed safety, tolerability and efficacy data from the first cohort of four patients and recommended continuing at a higher dose for the next four. ([our story](https://technooptimist.io/stories/safety-board-clears-lygenesis-ectopic-liver-trial-to-escalate-dose-b9f40901.md) · [original source](https://www.biospace.com/press-releases/data-and-safety-monitoring-board-approves-lygenesiss-phase-2a-clinical-trial-to-continue-and-dose-escalate-in-novel-trial-of-organ-regeneration))
- **2 Apr 2024**: LyGenesis doses first patient in Phase 2a trial growing ectopic livers in lymph nodes for end-stage liver disease. LyGenesis dosed the first patient in an open-label, dose-escalation Phase 2a trial of LYG-LIV-001, donor liver cells injected into lymph nodes that act as living bioreactors to grow ectopic liver. ([our story](https://technooptimist.io/stories/lygenesis-doses-first-patient-in-phase-2a-trial-growing-ectopic-livers-4b897fed.md) · [original source](https://appliedclinicaltrialsonline.com/view/first-patient-dosed-in-phase-iia-trial-of-regenerative-cell-therapy-for-end-stage-liver-disease))

## Partners, customers and investors

- Juvenescence (investor): Investor; its CEO Richard Marshall says the platform extends to diabetes, kidney disease and aging.
- Prime Movers Lab (investor): Investor.
- Houston Methodist (partner): Phase 2a trial site; principal investigator Dr. Constance Mobley.
- iTolerance (partner): Joint research from June 2022 on growing ectopic livers without systemic immune suppression (iTOL-201).

## People

- Michael Hufford, Co-founder and Chief Executive Officer
- Eric Lagasse, Chief Scientific Officer

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.